PLOS ONE

RESEARCH ARTICLE

Benzene exposure is associated with cardiovascular disease risk

Wesley Abplanalp[1,2☯¤a], Natasha DeJarnett[1,3☯¤b], Daniel W. Riggs[1,2], Daniel J. Conklin[1,2], James P. McCracken[1,2], Sanjay Srivastava[1,2], Zhengzhi Xie[1,2], Shesh Rai[4,5], Aruni Bhatnagar[1,2], Timothy E. O'Toole[1,2]*

1 Diabetes and Obesity Center, University of Louisville, Louisville, Kentucky, United States of America, **2** Institute of Molecular Cardiology, University of Louisville, Louisville, Kentucky, United States of America, **3** Department of Environmental and Occupational Health Sciences, University of Louisville, Louisville, Kentucky, United States of America, **4** Department of Bioinformatics and Biostatistics, University of Louisville, Louisville, Kentucky, United States of America, **5** Biostatistics Shared Facility, JG Brown Cancer Center, University of Louisville, Louisville, Kentucky, United States of America

☯ These authors contributed equally to this work.
¤a Current address: Institute of Cardiovascular Regeneration, Goethe University, Frankfurt, Germany
¤b Current address: American Public Health Association, Washington D.C., United States of America
* tim.otoole@louisville.edu



OPEN ACCESS

Citation: Abplanalp W, DeJarnett N, Riggs DW, Conklin DJ, McCracken JP, Srivastava S, et al. (2017) Benzene exposure is associated with cardiovascular disease risk. PLoS ONE 12(9): e0183602. https://doi.org/10.1371/journal.pone.0183602

Editor: Hiroyoshi Ariga, Hokkaido Daigaku, JAPAN

Received: April 17, 2017

Accepted: August 2, 2017

Published: September 8, 2017

Copyright: © 2017 Abplanalp et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: Data are available from doi:10.5061/dryad.qt71v.

Funding: This study was supported by ES0119217 and P50 HL120163-01, www.nih.gov.

Competing interests: The authors have declared that no competing interests exist.

Abstract

Benzene is a ubiquitous, volatile pollutant present at high concentrations in toxins (e.g. tobacco smoke) known to increase cardiovascular disease (CVD) risk. Despite its prevalence, the cardiovascular effects of benzene have rarely been studied. Hence, we examined whether exposure to benzene is associated with increased CVD risk. The effects of benzene exposure in mice were assessed by direct inhalation, while the effects of benzene exposure in humans was assessed in 210 individuals with mild to high CVD risk by measuring urinary levels of the benzene metabolite *trans*,*trans*-muconic acid (*t*,*t*-MA). Generalized linear models were used to assess the association between benzene exposure and CVD risk. Mice inhaling volatile benzene had significantly reduced levels of circulating angiogenic cells (Flk-1^+/Sca-1^+) as well as an increased levels of plasma low-density lipoprotein (LDL) compared with control mice breathing filtered air. In the human cohort, urinary levels of *t*,*t*-MA were inversely associated several populations of circulating angiogenic cells ($CD31^+/34^+/45^+$, $CD31^+/34^+/45^+/AC133^-$, $CD34^+/45^+/AC133^+$). Although *t*,*t*-MA was not associated with plasma markers of inflammation or thrombosis, *t*,*t*-MA levels were higher in smokers and in individuals with dyslipidemia. In smokers, *t*,*t*-MA levels were positively associated with urinary metabolites of nicotine (cotinine) and acrolein (3-hydroxymercapturic acid). Levels of *t*,*t*-MA were also associated with CVD risk as assessed using the Framingham Risk Score and this association was independent of smoking. Thus, benzene exposure is associated with increased CVD risk and deficits in circulating angiogenic cells in both smokers and nonsmokers.

Introduction

Benzene is a ubiquitous environmental pollutant. In the United States, it is one of the top 20 chemicals produced by industrial sources, which yearly release over 6.7 million pounds of benzene into the air [1,2]. Substantial amounts of benzene are also generated by mobile sources, and together, these emissions deliver high levels of atmospheric benzene, especially near point sources [3–5]. Humans are also exposed to benzene generated by the combustion of organic material, as found in mainstream or secondhand cigarette smoke. Mainstream cigarette smoke contains 35–70 ppm benzene, and even higher concentrations of benzene are generated from other tobacco products such as water pipes, cigars and pipe tobacco [6,7]. Therefore, humans are frequently exposed to high levels of benzene generated from indoor and outdoor sources [8].

Though benzene is present at high concentrations in air pollutants known to increase CVD risk, little is known about the cardiovascular effect of benzene per se. Cardiovascular tissues are highly sensitive to inhaled pollutants and several studies have shown that inhalation of toxic substances such as cigarette smoke and particulate matter ($PM_{2.5}$) cause significant cardiovascular injury [9–13]. Indeed, myocardial infarction and stroke are the leading causes of death in smokers, and more than 70% of excessive premature mortality associated with ambient particulate air pollution is due to cardiovascular causes [9]. Hence, we measured urinary levels of the benzene metabolite *trans*, *trans*-muconic acid (*t*,*t*-MA) in individuals with mild to high CVD risk and examined associations with traditional CVD risk factors and circulating angiogenic cell populations, which are reported to maintain vascular integrity and predict CV events and mortality [14–16]. Our results show that benzene exposure is associated with a suppression of circulating angiogenic cells (CACs), cells that have been found to be sensitive to inhaled pollutants and are predictive of cardiovascular events and increased CVD risk in humans. A suppression of CAC levels was also observed in mice exposed directly to benzene, supporting the biological plausibility of a direct effect of benzene on circulating CAC levels. Taken together, these observations support that notion that exposure to benzene could result in significant cardiovascular injury and increase the risk of developing cardiovascular disease.

Materials and methods

Murine inhalation exposure

Male C57BL/6 mice (10 weeks old, n = 10/treatment) were purchased from the Jackson Laboratory and housed in AALAC- and USDA-accredited facilities at UofL. The animals had access to food and water *ab libitum*, except during exposure periods. Benzene atmospheres were generated from a certified permeation tube system (Kin-Tek, LaMarque, TX) into a custom exposure chamber (Teague Enterprises, Inc.) as previously described for acrolein [17]. Exposures to benzene (50 ppm) or HEPA-filtered air were for 6 hours/day x 5 days/week x 6 weeks. Mice were euthanized by *i.p.* injection with pentobarbital at a dose of 150mg/kg. After injection, the animals were placed in a clean cage until they lacked response to physical stimuli, which was approximately 8 minutes post-injection. All procedures were approved the University of Louisville IACUC 16688.

Human study population

Individuals (>18 years of age) with mild to high CVD risk were recruited from the University of Louisville Hospital and affiliated clinic system between October 2009 and March 2011. All accessible patients (nearly 900 individuals) visiting the clinics during this time period were pre-screened through medical records review prior to recruitment to exclude individuals that

did not meet the enrollment criteria. In addition, persons unwilling or unable to provide informed consent or with significant and/or severe comorbidities were excluded. Exclusion criteria included: significant chronic lung, liver, kidney, hematological, or neoplastic disease, chronic neurological or psychiatric illness, chronic infectious disease such as HIV or hepatitis, severe coagulopathies, drug/substance abuse, and chronic cachexia. Pregnant women, prisoners, and other vulnerable populations were also excluded from the study. Patients who met the enrollment criteria (n = 210) and gave written consent were consented and administered a questionnaire (S1 File), which included demographic information, residential address, smoking status and history, secondhand smoke exposure, alcohol consumption, physical activity status, medication usage, and CVD history including incidence of heart attack, heart failure, angina, hypertension, hypercholesterolemia, diabetes, stroke, revascularization, arrhythmia, peripheral artery disease, aortic aneurism, and bleeding disorders. Medical records were reviewed to verify data obtained from subject interview. Median household income was designated at the U.S. Census Bureau block group geographic level. The study was approved by the University of Louisville Institutional Review Board (IRB 09.0174).

Sample collection and analysis

Murine blood was collected by cardiac puncture after euthanasia. In mice, circulating levels of Flk-1^+/Sca-1^+ cells were measured by flow cytometry [15]. Fasting plasma levels of low-density lipoprotein (LDL) and high-density lipoprotein (HDL) were measured on the Cobas Mira 5600 Autoanalyzer using commercially available kits (Sekisui Diagnostics). Human blood was obtained from participants at the time of visit and 15 phenotypically distinct populations were quantified by flow cytometry [14]. Platelet-leukocyte aggregates were identified by flow cytometry and quantified as a percentage of total events double positive for $CD41^+$ and $CD45^+$ [14, 15]. Fibrinogen (STA Fibrinogen Kit), and C-reactive protein (VITROS kit) were measured on the Cobas Mira.

Measurement of urinary metabolites

The concentration of *t*,*t*-MA in the urine was measured by GC/MS using modifications of a previously described method [18]. Briefly, 1.0 nanomole of [D4] muconic acid (CDN isotopes) was added to 0.5mL urine in an 8mL glass vial. After addition of 50μL of HCl, the mixture was extracted with 1mL ethyl acetate. Sodium sulfate was added to the ethyl acetate layer to remove excess water. The ethyl acetate was then transferred to a 2mL vial and dried under N_2. The *t*,*t*-MA was derivatized by the addition of 100μL of acetonitrile and 50μL of BSTFA, and the sample was heated at 60° C for 30 min. The derivatized sample was injected directly in the GC (Agilent Technologies, 6890 N), equipped with a mass detector (Agilent Technologies 5973). The concentration of *t*,*t*-MA in the sample was calculated from the ratio of TMS-muconic acid (m/z 271) and [D4]TMS-muconic acid (m/z 275). Urinary levels of *t*,*t*-MA were normalized to creatinine, which was measured using a commercial kit (Thermo Fisher, Infinity Creatinine Kit) with a Cobas Mira 5600 Autoanalyzer.

Cotinine was measured using a GC/MS (Agilent Technologies) method [19]. One mL of urine from self-reported current non-smokers, or 0.25 mL of urine from self-reported current smokers (diluted with 0.75 mL of deionized water) was pipetted into Teflon vials. Either 0.2 nmoles (non-smokers) or 0.5 nmoles (smokers) of the internal standard of D-3 cotinine in 0.175 mL of methanol was added followed by the addition of 0.05 mL of 0.1M NaOH and 0.325 mL of chloroform. This mixture was then centrifuged at 13000 rpm for 4 min. After discarding the aqueous layer, 100 mg of sodium sulfate was added to remove excess water, briefly mixed, and the solution was allowed to sit at room temperature for 1 min. The clear organic

extract was transferred to a gas chromatography vial and 0.001 mL was injected to the GC. The *m/z* values of ions used to monitor cotinine were: 176 (cotinine) and 179 (D-3 cotinine).

Urinary levels of 3-HPMA were quantified using GC/MS as previously described [14]. For each assay, 1 mL urine was combined with 2.5 nmol of ^{13}C HPMA (internal standard) and added to an Oasis Max Solid Phase Extraction column for purification. The column protocol included sequential application of: 6 mL MeOH, 6 mL 2% NH_4OH, urine, 6 mL 2% NH_4OH, and 6 mL MeOH. The column was then dried with N_2, and washed with 6 mL 2% formic acid and eluted with 30% MeOH in 2% formic acid. The 3-HPMA fraction was lyophilized and reconstituted in 1 mL water. The solution was then syringe-filtered and purified using HPLC. The 3-HPMA fraction was lyophilized and subsequently derivitized with 40 μL acetonitrile and 40 μL N,O-Bis(trimethylsilyl)trifluoroacetamide (BSTFA) for 1 h at 60°C. One μL of the sample was applied to GC/MS (Agilent 6890N) for quantification. The ion fragments 366 (3-HPMA) and 369 (C^{13} HPMA) were compared for quantification. The values of 3-HPMA were normalized to creatinine.

Statistical analyses

In the human study, the primary exposure variable, urinary *t*,*t*-MA, was examined for association with the primary outcome variable (CAC counts) and secondary outcome variables (e.g. CVD risk factors, fibrinogen). The levels of *t*,*t*-MA in the urine were stratified into tertiles of high, medium, and low values based on the distribution of the *t*,*t*-MA values for the entire cohort. For discreet categorical predictor variables (i.e. gender, medication history) frequencies and percentages were computed and compared among the primary exposure variable tertiles using the Chi Square test. For the continuous predictor variables, mean and standard deviation values were compared amongst the *t*,*t*-MA tertiles using ANOVA. Due to higher variability in continuous predictor variables (i.e. hsCRP, fibrinogen), p-values were calculated from log transformed data. Predictors associated at $p<0.05$ level with the exposure variable were considered potential confounders and corrected for in the final models.

Generalized linear models were used to examine whether the levels of CACs were associated with urinary *t*,*t*-MA levels, after adjusting for specific variable (ethnicity, HLD and cotinine). CAC levels appeared to follow the gamma distribution; therefore, generalized linear models that assessed circulating angiogenic cells as the dependent variable utilized the gamma probability distribution and the log link function. In preliminary analysis, we examined the association of 15 different populations of CACs with *t*,*t*-MA values. Four of these populations were highly correlated with urinary *t*,*t*-MA levels, and were therefore selected for further analysis.

Subset analyses (e.g. non-smokers, ethnicity) determining CAC and *t*,*t*-MA associations were also performed. Significant other predictors at $\alpha = 0.05$ were included in the preliminary model. However, the final model contains only predictors that remained significant at five percent. These demographic groups displayed associations with the primary exposure variable, and therefore needed further analysis to determine unique relationships to the primary outcome variable (CACs). The non-smoker population was adjusted for ethnicity, hyperlipidemia and cotinine while ethnic groups (African Americans and Whites) were adjusted for hyperlipidemia and cotinine based on results from Table 1. Given that the non-smokers and different ethnic groups had different demographic associations with *t*,*t*-MA for each CAC population, a subset analysis was performed to interrogate the relationship between CACs and *t*,*t*-MA in the context of race in Table 2. To assess the contribution of benzene exposure from smoking we regressed *t*,*t*-MA against common metabolites of cigarette smoke exposure (cotinine and 3-HPMA) in Fig 1. To further graphically display the difference between smokers and non-smokers in Fig 1, we utilized the commonly used cut-point of 200 μg cotinine/g creatinine–

Table 1. Demographics and CVD risk history stratified by *t,t*-MA.

Categorical Variable–n (%)	Total n = 210	Low *t,t*-MA n = 70	Medium *t,t*-MA n = 70	High *t,t*-MA n = 70	*P* value	
Gender					0.440	
Female	101 (48)	32 (46)	38 (54)	31 (44)		
Male	109 (52)	38 (54)	32 (46)	39 (56)		
Ethnicity					0.001	*
White	118 (56)	26 (37)	43 (61)	49 (70)		
African American	88 (42)	42 (60)	27 (39)	19 (27)		
Hispanic/Latino	4 (2)	2 (3)	0 (0)	2 (3)		
CVD Risk Factors						
Hypertension	168 (81)	58 (84)	57 (83)	54 (78)	0.677	
Hyperlipidemia	128 (63)	39 (58)	37 (54)	52 (75)	0.021	*
Diabetes	54 (26)	18 (26)	19 (28)	17 (25)	0.928	
Obese	118 (58)	38 (57)	40 (59)	40 (58)	0.969	
Current smoker (self-report)	82 (39)	16 (23)	33 (48)	33 (47)	0.003	*
Never smoked (self-report)	57 (27)	25 (36)	16 (23)	16 (23)	0.132	
Former smoker (self-report)	69 (33)	28 (40)	20 (29)	21 (30)	0.311	
Environmental smoke (self-report)	38 (30)	10 (19)	13 (37)	15 (41)	0.053	
High CVD risk category	166 (79)	48 (69)	59 (84)	59 (84)	0.031	*
Medical History						
Myocardial infarction	70 (34)	21 (30)	24 (35)	25 (36)	0.782	
Stroke	20 (10)	7 (10)	3 (4)	10 (14)	0.137	
CABG/ PCI/ Stents	56 (27)	14 (20)	17 (25)	25 (36)	0.107	
Heart failure	37 (18)	12 (18)	12 (17)	13 (19)	0.972	
Medication						
ACE inhibitor	112 (55)	35 (51)	40 (59)	37 (54)	0.635	
Angiotensin-receptor blockers	12 (6)	5 (7)	4 (6)	3 (4)	0.779	
Aspirin	116 (57)	35 (51)	40 (59)	41 (60)	0.476	
Beta-blocker	129 (63)	41 (59)	44 (65)	44 (65)	0.760	
Calcium-channel blockers	46 (22)	14 (20)	17 (25)	15 (22)	0.801	
Diuretics	79 (39)	25 (36)	31 (46)	23 (34)	0.330	
Statins	108 (53)	31 (45)	34 (50)	43 (63)	0.086	
Vasodilator	47 (23)	16 (23)	20 (29)	11 (16)	0.185	
Continuous Variable–mean (SD)	**Total**	**Low *t,t*-MA**	**Medium *t,t*-MA**	**High *t,t*-MA**	***P* value**	
Age (years)	51 (10)	52 (11)	49 (10)	52 (10)	0.247	
Cotinine (μg/g creatinine)	521 (1050)	146 (373)	686 (1431)	725 (963)	<0.001	*
Framingham Risk Score (FRS)	8 (8)	7 (7)	7 (7)	12 (9)	0.259	
Lymphocyte count X 10^4	13 (9)	13 (9)	13 (9)	14 (10)	0.724	
Thrombosis						
Fibrinogen (mg/dL)	346 (109)	355 (128)	345 (111)	339 (82)	0.778	
Platelet-leukocyte aggregates	11 (6)	11 (5)	10 (5)	11 (7)	0.718	
Inflammation						
hsCRP (mg/L)	5 (5)	5 (5)	4 (4)	5 (5)	0.590	
Median household income (X $1000 USD)	31 (18)	29 (18)	35 (20)	30 (16)	0.066	

Tertiles are based on log transformed *t,t*-MA values. Ranges for the tertiles for low, medium and high *t,t*-MA levels are 0.0132–0.0615mg/g creatinine, 0.0625–0.155mg/g creatinine and 0.159–2.85mg/g creatinine, respectively. Individuals with a body mass index $\geq$ 30 were considered obese. Current, never, and former smokers were identified on the basis of self-reported smoking status. Individuals with high FRS category had a FRS $\geq$ 20 or had previously experienced a cardiovascular event. Vasodilators include nitrates and hydralazine. Platelet-leukocyte aggregates are defined as the percent of $CD41^+/CD45^+$ events. The sum of CVD risk factors includes the following: Framingham risk factors: age $\geq$ 40 years, male gender, current smoker, hypertension, hyperlipidemia, and diabetes. Median household income is in United States dollars (USD), at the US Census block group level. CABG, coronary artery bypass graft; PCI, percutaneous coronary intervention; ACE, angiotensin-converting-enzyme; hsCRP, high sensitivity C-reactive protein
* p<0.05.

https://doi.org/10.1371/journal.pone.0183602.t001

Table 2. Association between *t,t*-MA and CACs.

***t,t*-MA Regression**	**Cell type-2 ($CD31^+/34^+/45^+$)**	**Cell type-8 ($CD31^+/34^+/45^+/AC133^-$)**	**Cell type-11 ($AC133^+$)**	**Cell type-14 ($CD34^+/45^+/AC133^+$)**
Total Population, *adjusted for ethnicity, hyperlipidemia, and cotinine* n = 210				
Change (%)	-8.739	-8.923	-0.4687	-8.936
P value	< 0.001*	<0.001*	0.870	<0.001*
Non-smokers, *adjusted for ethnicity, hyperlipidemia, and cotinine* n = 128				
Change (%)	-9.359	-9.365	-2.621	-8.955
P value	<0.001*	<0.001*	0.364	<0.001*
White, *adjusted for hyperlipidemia, and cotinine* n = 118				
Change (%)	-8.883	-8.848	-3.363	-8.405
P value	0.002*	0.002*	0.068	0.016*
African American, *adjusted for hyperlipidemia and cotinine* n = 88				
Change (%)	-6.770	-7.239	5.753	-9.973
P value	0.253	0.212	0.008*	<0.001*

Change represents percent change per 0.1mg *t,t*-MA/g creatinine.

*: p<0.05

https://doi.org/10.1371/journal.pone.0183602.t002

where individuals with cotinine levels below 200 μg cotinine/g creatinine were considered non-smokers. These cut-points generated from the cotinine data were used in Fig 1B when displaying the relationship between *t,t*-MA levels and 3-HPMA.

To adequately describe the phenotype of the population in relation to CVD, the population was dichotomized into low and high risk strata. An FRS below 20 was considered low risk. Individuals with FRS above 20 or those receiving secondary preventive care were assigned to the high risk category. Differences in mean *t,t*-MA values among the risk strata were compared using a two-sample *t*-test analysis. To evaluate the association between cigarette-independent benzene exposure and CVD risk, only the non-smokers in the high risk category were examined. For data management and statistical analyses, the IBM SPSS Statistics version 21.0 for Windows was used. For our murine exposure data analysis, the levels of Flk-1$^+$/Sca-1$^+$ cells (CACs), LDL and HDL mice were compared with the HEPA-filtered air control mice using a two sample t-test analysis.

Results

Cardiovascular effects of benzene inhalation in mice

While the carcinogenic [20, 21] and hemato-toxic [22–24] effects of benzene are known, it is not clear if exposure to this aromatic also contributes to cardiovascular disease. To begin to



Fig 1. Association between cigarette smoke exposure and *t,t*-MA levels. Associations of *t,t*-MA with cotinine (A) and 3-HPMA (B) were established by regression analysis. Cigarette smoke is the major source of benzene exposure in the smoking sub-group.

https://doi.org/10.1371/journal.pone.0183602.g001



Fig 2. Volatile benzene exposure decreases murine CACs and increases lipoprotein levels. (A) Flk-1+/Sca-1+ cells were measured in C57Bl/6 mice after 6 weeks of exposure to volatile benzene (50ppm, 6h/d) and filtered air. The benzene exposed animals showed an approximate 48% decrease in these cells after six weeks of benzene exposure. Levels of total plasma cholesterol (B), LDL (C), HDL (D), triglycerides (F) were also quantified in the exposed mice. An LDL:HDL ratio was also calculated (E). All plasma variables except triglycerides were elevated in benzene-exposed mice compared with the filtered air exposed controls. n = 22-39/treatment group; *: p<0.05.

https://doi.org/10.1371/journal.pone.0183602.g002

examine this, we first assessed the level of circulating angiogenic cells (Flk+/Sca+) in mice inhaling volatile benzene. Levels of Flk+/Sca+ cells serve as a suitable indicator of vascular health as pauperization of analogous cells in humans is associated with deficits in vascular repair and is predictive of cardiovascular event and mortality. We found that, in mice exposed to benzene, Flk-1+/Sca-1+ cells were significantly suppressed (p = 0.002). In comparison with mice inhaling filtered air, those mice exposed to benzene had, on average, 3.4% lower levels of Flk-1+/Sca-1+ cells per 1.0 mg *t*,*t*-MA/g creatinine (Fig 2A). We further found that benzene induced dyslipidemia. Total cholesterol was elevated in benzene-exposed mice (120.0±7.1mg/dL) compared with mice breathing filtered air (107.0±4.7mg/dL) (Fig 2B). Benzene-exposed mice had higher plasma LDL (34.2±4.1 mg/dL) than mice breathing filtered air (25.6±3.3mg/dL) (Fig 2C). HDL levels in mice exposed to benzene (69.4±7.3 mg/dL) were 7.6% higher than in mice exposed to filtered air (64.5±4.6mg/dL) (Fig 2D). As a result, there was a 23% increase in the LDL:HDL ratio in benzene-exposed mice (Fig 2E). Triglyceride levels were unaffected (Fig 2F). Finally, benzene induced significant blood cell cytopenia (Table 3). Taken together, these results indicate that benzene inhalation in mice increased several indices commonly used to assess CVD risk in humans.

Human cohort characteristics

To directly assess associations between benzene exposure and cardiovascular health in humans, we enrolled a cohort of subjects with CVD or at risk of developing CVD (Table 1). The study cohort was middle-aged (51±10 years), with a slightly higher proportion of males (n = 109, 52%) and Whites (n = 118, 56%). The cohort included both current (n = 82, 39%) and former (n = 57, 27%) smokers. A majority of the participants was diagnosed with hypertension (n = 168, 81%), hyperlipidemia (n = 128, 63%), or obesity (body mass index $\geq$ 30, n = 118, 58%). Several participants were taking medications, including angiotensin converting

Table 3. Complete blood count of mice exposed to volatile benzene or HEPA-filtered air for six weeks.

Parameter		HEPA Mean (SD)	Benzene Mean (SD)	p-value	
Leukocytes					
	WBC (k/mL)	2.200 (0.782)	1.380 (0.099)	0.014	*
	NE (k/mL)	0.379 (0.140)	0.199 (0.099)	0.006	*
	LY (k/mL)	1.742 (0.641)	1.009 (0.246)	0.009	*
	MO (k/mL)	0.073 (0.040)	0.041 (0.015)	0.037	*
	EO (k/mL)	0.002 (0.004)	0.004 (0.008)	0.569	
	BA (k/mL)	0.003 (0.005)	0.002 (0.004)	0.628	
	NE (%)	17.57 (3.3)	14.59 (6.80)	0.234	
	LY (%)	79.16 (3.77)	81.49 (7.25)	0.382	
	MO (%)	2.92 (1.05)	3.39 (0.83)	0.282	
	EO (%)	0.106 (0.115)	0.041 (0.592)	0.215	
	BA (%)	0.146 (0.170)	0.000 (0)	0.024	*
Erythrocytes					
	RBC (M/mL)	8.52 (0.60)	7.10 (2.40)	0.098	
	HGB (g/dL)	11.6 (0.8)	9.7 (3.6)	0.126	
	HCT (%)	38.0 (2.5)	32.8 (11.7)	0.202	
	MCV (fL)	44.6 (0.8)	45.8 (2.1)	0.112	
	MCH (pg)	13.6 (0.5)	13.4 (0.7)	0.613	
	MCHC (g/dL)	30.5 (1.4)	29.4 (1.9)	0.146	
Thrombocytes					
	RDW (%)	17.2 (0.5)	16.7 (0.8)	0.135	
	PLT (k/mL)	768 (71)	601 (195)	0.028	*
	MPV (fL)	4.4 (0.1)	4.5 (0.1)	0.513	

*: p<0.05

n = 10 animals/treatment

https://doi.org/10.1371/journal.pone.0183602.t003

enzyme (ACE) inhibitors (n = 112, 55%), beta-blockers (n = 129, 63%), and/or statins (n = 108, 53%). The median annual household income ($31,000) was lower than the median household income for Jefferson County of $46,298 [25].

The cohort was stratified into three *t*,*t*-MA levels (Table 1). Those stratified did not differ in age, gender, hypertension, diabetes mellitus, obesity, medical history, medication use, FRS, lymphocyte count, thrombosis, inflammation, or median household income. Compared with African Americans and Hispanic/Latinos, Whites were more likely to have higher *t*,*t*-MA levels ($p = 0.001$). Individuals who smoked or those with hyperlipidemia were more likely to have higher *t*,*t*-MA ($p = 0.003$, and $p = 0.021$, respectively). Cotinine levels were significantly higher in the high *t*,*t*-MA group than in the low *t*,*t*-MA group ($p<0.001$). Compared with low risk individuals (FRS $<$ 20), high risk individuals (with FRS $>$ 20), or those under secondary preventive care were more likely to have higher *t*,*t*-MA ($p = 0.031$).

Association between *t*,*t*-MA and tobacco smoke exposure

To examine the link between tobacco smoke exposure and benzene, *t*,*t*-MA levels were regressed against cotinine, a metabolite of nicotine, and 3-HPMA, a metabolite of acrolein. The unadjusted regressions demonstrate positive associations between *t*,*t*-MA and both cotinine ($p<0.001$) and 3-HPMA ($p<0.001$) (Fig 1). On average, *t*,*t*-MA levels were 0.09% higher for every 1.0% increase in cotinine. In addition, the levels of 3-HPMA were 0.3% higher with

1.0% increase in cotinine levels, indicating a close association between smoking and acrolein exposure. Overall, *t,t*-MA was higher in smokers, suggesting that cigarette smoke is the major source of benzene exposure.

Association between CACs and *t,t*-MA

Unlike mouse CACs which are defined by two markers, we used four markers in a flow cytometry-based strategy to identify 15 subtypes of human CACs [26]. To examine the association between benzene and these CAC subtypes, we constructed generalized linear models by regressing cell levels against *t,t*-MA (Table 2). After adjustment for ethnicity, hyperlipidemia, and cotinine, CAC-2 ($CD31^{+}/34^{+}/45^{+}$), CAC-8 ($CD31^{+}/34^{+}/45^{+}/AC133^{-}$), and CAC-14 ($CD34^{+}/45^{+}/AC133^{+}$) were significantly associated with *t,t*-MA. For each 0.1mg/g creatinine increase in *t,t*,-MA, there was a 8.7%, 8.9% and 9% decrease in CAC-, 2, 8 and 14, respectively. In non-smokers, after adjustment for ethnicity and hyperlipidemia, CAC-8 and CAC-14 were inversely associated with *t,t*-MA, indicating that even in non-smokers, exposure to benzene is associated with suppressed CAC levels.

Because *t,t*,-MA varied with ethnicity (Table 1), we stratified the cohort into Whites and African-Americans. After adjustment for hyperlipidemia and cotinine in Whites, CAC-2, 8 and 14 were inversely associated with *t,t*-MA. We estimate that for each 0.1 mg/g creatinine increase in *t,t*,-MA there was an 8.9% decrease in CAC-2, an 8.8% decrease in CAC-8, and an 8.4% decrease in CAC-14. Given that the demographic features of the African-Americans in the cohort were significantly different from the White population, a different set of adjustment factors was deemed more appropriate. After adjustment for gender, diuretics, calcium channel blockers, hypertension, revascularization, median household income, and cotinine, levels of cell type-2 ($\beta = -1.444$, $p = 0.041$), cell type-8 ($\beta = -1.616$, $p = 0.029$), and cell type-14 ($\beta = -8.968$, $p = 0.001$) were inversely associated with *t,t*-MA in the African-American population. In addition, *t,t*-MA levels were positively associated with cell type-11 ($AC133^{+}$, $\beta = 1.615$, $p = 0.009$) within this population.

Association of *t,t*-MA and CVD risk

To determine whether benzene exposure was associated with CVD risk, we stratified into low or high risk categories. Individuals with low CVD risk had significantly lower levels of *t,t*-MA than those in the high risk category (0.14±0.03 vs 0.19±0.03 mg *t,t*-MA /g creatinine) (Fig 3A). Because FRS estimates of CVD risk include smoking, this association may be partly due to benzene exposure from smoking. Hence, we examined the association between benzene



Fig 3. Association between *t,t*-MA and CVD risk. Associations between low (< 20; n = 44) and high (≥ 20 or experienced a cardiovascular event; n = 166) Framingham Risk Score and *t,t*-MA were determined for the total population (A; p = 0.024) and in non-smokers (B; p = 0.006).

https://doi.org/10.1371/journal.pone.0183602.g003

exposure and *t*,*t*-MA. In non-smokers, we found that low CVD risk had significantly lower *t*,*t*-MA than those in the high risk category (0.10±0.03 mg *t*,*t*-MA/g creatinine vs. 0.21±0.04 mg *t*,*t*-MA/g creatinine) (Fig 3B). Plasma indices of inflammation and thrombosis, such as fibrinogen (p = 0.778), platelet leukocyte aggregates (p = 0.718), and hsCRP (p = 0.590) were not associated with *t*,*t*-MA or cotinine.

Discussion

The major finding of this study is that benzene exposure is associated with increased cardiovascular disease risk and injury. This risk may be due in part to dyslipidemia and CAC pauperization as subjects in our human cohort with higher levels of *t*,*t*-MA had higher LDL levels and deficits of CACs which are indicative of vascular repair and predictive of cardiovascular events and mortality [16]. In addition we found that *t*,*t*-MA levels were associated with elevated CVD risk scores. Finally, while *t*,*t*-MA levels were higher in smokers than non-smokers, *t*,*t*-MA levels in non-smokers also showed a robust negative association with CAC levels. Collectively, these observations suggest that although smoking represents a major source of benzene exposure, exposure to benzene from other sources also likely induces cardiovascular injury and decreases vascular repair.

Although the health effects of occupational exposure to high levels of benzene have been studied, the effects of benzene at levels present in ambient air or tobacco smoke remain unclear. In addition, the contribution of benzene to the overall toxicity of tobacco smoke has not been assessed, and little is known about the cardiovascular effects of benzene. Our results showing that smokers had higher *t*,*t*-MA than non-smokers are consistent with previous reports and confirm that smoking is a major source of benzene [27, 28]. Indeed, in our analysis of smoking-derived metabolites (cotinine, *t*,*t*-MA and 3-HPMA), high *t*,*t*-MA was more closely associated with high cotinine than 3-HPMA (Fig 1B), suggesting that smokers and non-smokers could be more accurately distinguished by *t*,*t*-MA levels than 3-HPMA levels. This could be reflective of the fact that smoking is a major source of high level benzene exposure, whereas high level acrolein metabolites may arise from a variety of exogenous (e.g., food) or endogenous (e.g., myeloperoxidase or lipid peroxidation) sources [29–31]. Furthermore, our observation that *t*,*t*-MA was associated with CVD injury supports the notion that the harmful cardiovascular effects of smoking may be in part due to the presence of benzene. In our fully adjusted model, we found the association between *t*,*t*-MA and CACs was independent of cotinine. This may be due to differences in cigarette brand constituents or smoking behavior; differences that could lead to dissimilar levels of benzene exposure even at similar doses of inhaled nicotine.

Our observation that CVD risk was associated with *t*,*t*-MA in non-smokers suggests that benzene may be linked to cardiovascular injury, even in the absence of exposure to other tobacco smoke constituents; a view supported by our murine studies showing that exposure to benzene alone is sufficient to reduce vascular reparative cells. Hence, exposure to benzene, regardless of its source, and independent of the presence of other co-pollutants and toxicants, is predictive of cardiovascular injury and is associated with increased CVD risk. In non-smokers, we found that the *t*,*t*-MA ranged from 0.01 to 2.85 mg/g creatinine, which corresponds to an exposure range of benzene between 2 to 800 ppb [27]. The average ambient air concentration of benzene in most US cities is expected to range from 10 and 20 ppb, albeit higher levels could result from additional sources such as vehicle exhaust, gasoline, paints, adhesives, and solvents [4, 32–35]. Although exposure to high levels of benzene has been linked to acute myeloid and acute nonlymphocytic leukemias, low dose exposure (< 1 ppm) has been found to be associated with hematoxic effects and lymphohematopoietic (LH) cancers [23, 24]. Therefore,

our observation showing an association between cardiovascular outcomes and benzene exposures corresponding to <1 ppm suggest that adverse CVD outcomes are at least as likely as LH cancers and hematoxicity in low dose exposures and may be more prevalent in the general population exposed to ambient benzene levels.

In both humans and mice we found that benzene exposure was associated with altered plasma lipoprotein levels. This finding suggests that dyslipidemia may be a significant outcome of benzene exposure, driving vascular inflammation and promoting the development of atherosclerotic lesions. Further cardiovascular risk derives from depletion of CACs, which are important for repair and regeneration of vascular tissue and are strongly associated with poor cardiovascular outcomes in susceptible individuals [16]. Previous studies have shown that CACs are highly sensitive to pollutant exposure as their abundance in circulation decreases upon exposure to tobacco smoke, acrolein and $PM_{2.5}$ [15, 17, 36]. In the current study we found that benzene exposure was associated with low levels of specific CAC subpopulations (cell types 2, 8, 14) in humans and decreased $Flk^+/Sca\text{-}1^+$ cells in mice. Thus, these findings identify CACs as a new and sensitive target of benzene and suggest that both hematopoietic and non-hematopoietic stem cell populations can be affected by exposure. Given that both CVD risk and hematoxicity are sensitive to a similar range of benzene concentrations (*vide supra*), it seems likely that there might be a common locus of injury that affects primitive progenitor cells (i.e. hemangioblasts) that differentiate into both hematopoietic precursor and angiogenic progenitor cells. While further experiments are required to test this possibility, the high sensitivity of $CD45^+$, but not $CD45^-$ cells support the hypothesis that benzene exposure specifically affects hematopoietic cells and that depletion of CACs may result from the hematoxicity of benzene. The $AC133^+$ cell population has been shown to enhance re-endothelialization of vascular lesions when transplanted into mice and a 58% decrease in these cells predicted a 300% increase in CV mortality [16, 37]. Given this relationship, one might estimate that every 20 ppb increase in atmospheric benzene is likely to be associated with a 33% increase in CV mortality. Because benzene emissions associated with traffic pollution have been linked to the onset of acute myocardial infarction, our results suggest that benzene exposure, through suppression of CACs, may be a significant, and heretofore overlooked, CVD risk factor and pervasive trigger of acute cardiovascular events [38].

Our study has several strengths. It identifies a novel, inverse association between benzene and CACs in both humans and mice. Additional strengths of the study are assessments of individual exposure and risk indices, as exposure was estimated for each individual, based on urinary *t*,*t*-MA. Because blood and urine samples used to analyze CACs and *t*,*t*-MA were collected at the same time, we could concurrently evaluate both parameters which minimized mismatch due to temporal variations. Associations between *t*,*t*-MA and CACs were robust and even after correcting for multiple comparisons of 15 cell types, they remained significant ($p<0.015$). Moreover, the relationship between benzene and CVD risk was not obtained from a post-hoc analysis of the data, but was examined to test an *a priori* hypothesis developed on the basis of previous data showing that exposure to benzene alters stem cell differentiation and growth [39–41]. This study also has some limitations. Although the cohort size is relatively large for one assessing CACs, it is fairly small for a study of CVD or environmental epidemiology. The cross-sectional design of the study is limited in its ability to determine causality. Moreover, the magnitude of benzene exposure varied. The effects of increased exposure may have been missed in a longitudinal prospective study if the exposure is not maintained throughout the observation period. However, the effects of simultaneous exposures are likely to be more apparent in a cross-sectional design, although long-term trends may be difficult to interpret.

Although most *t*,*t*-MA arises directly from the metabolism of benzene by CYP2E1, it can also be generated at low levels by the metabolism of anti-microbial agents (e.g., sodium sorbate) which could lead to exposure misclassification. Another limitation of the study may be analysis from only a single urine sample from each subject. Therefore, our measurements may reflect a limited exposure. However, single time point urine collection samples correlate well with 24 h collection [42]. Circadian fluctuation in the expression of CYP2E1 or proximate environmental exposure were mitigated by collecting samples during the same time of day in the same laboratory [43]. Variability could also arise from individual differences in smoking behavior and metabolism of smoke constituents, which are not accounted for in our study. Genetic variation or dietary differences may alter CYP2E1 expression and activity, which would therefore alter the exposure to benzene metabolites [44].

Nevertheless, our results have wide implications as they suggest that exposure to benzene from any source could increase CVD risk. While a few studies have suggested a relationship between benzene exposure and insulin resistance or hypertension, these results have not been confirmed in animal models, or in well-controlled studies [45, 46]. Because benzene is a ubiquitous pollutant, further evaluation of its cardiovascular effects could inform exposure avoidance guidelines and regulatory policy to limit emissions by automobiles and industrial processes or to regulate tobacco products. Given the widespread exposure to benzene, even a modest decrease in exposure may substantially reduce the global burden of cardiovascular disease.

Supporting information

S1 File. Questionnaire given to study participants.
(DOCX)

Author Contributions

Conceptualization: WA ND DJC DWR SS SR AB TEO.

Data curation: WA ND DWR DJC SS SR AB TEO.

Formal analysis: WA ND DWR JPM.

Funding acquisition: DJC SS AB TEO.

Investigation: WA ND DWR JPM ZX TEO.

Methodology: WA ND DWR DJC JPM SS ZX SR AB TEO.

Project administration: WA ND DWR DJC JPM SS SR AB TEO.

Resources: DJC SS SR AB TEO.

Supervision: DJC SS SR AB TEO.

Validation: DWR SR AB.

Writing – original draft: WA ND AB TEO.

Writing – review & editing: WA ND DWR DJC JPM SS SR AB TEO.

References

1. ATSDR. Toxicological Profile for Benzene. In: Registry AfTSaD, editor. Atlanta, GA2005.

2. Inventory TR. Toxics Release Inventory (TRI) Data: Environmental Defense Fund; 2016 [Benzene Release].
3. Clayton CA, Pellizzari ED, Whitmore RW, Perritt RL, Quackenboss JJ. National Human Exposure Assessment Survey (NHEXAS): distributions and associations of lead, arsenic and volatile organic compounds in EPA region 5. J Expo Anal Environ Epidemiol. 1999; 9(5):381–92. PMID: 10554141
4. Fraser MP, Cass GR, Simoneit BRT. Gas-phase and particle-phase organic compounds emitted from motor vehicle traffic in a Los Angeles roadway tunnel. Environ Sci Technol. 1998; 32(14):2051–60.
5. Morello-Frosch RA, Woodruff TJ, Axelrad DA, Caldwell JC. Air toxics and health risks in California: the public health implications of outdoor concentrations. Risk Anal. 2000; 20(2):273–91. PMID: 10859786
6. Jacob P, 3rd, Abu Raddaha AH, Dempsey D, Havel C, Peng M, Yu L, et al. Comparison of nicotine and carcinogen exposure with water pipe and cigarette smoking. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2013; 22(5):765–72.
7. Appel BR, Guirguis G, Kim IS, Garbin O, Fracchia M, Flessel CP, et al. Benzene, benzo(a)pyrene, and lead in smoke from tobacco products other than cigarettes. American journal of public health. 1990; 80 (5):560–4. PMID: 2327532
8. Hattemer-Frey HA, Travis CC, Land ML. Benzene: environmental partitioning and human exposure. Environ Res. 1990; 53(2):221–32. PMID: 2253601
9. Pope CA, 3rd, Turner MC, Burnett RT, Jerrett M, Gapstur SM, Diver WR, et al. Relationships between fine particulate air pollution, cardiometabolic disorders, and cardiovascular mortality. Circ Res. 2015; 116(1):108–15. https://doi.org/10.1161/CIRCRESAHA.116.305060 PMID: 25348167
10. Newby DE, Mannucci PM, Tell GS, Baccarelli AA, Brook RD, Donaldson K, et al. Expert position paper on air pollution and cardiovascular disease. Eur Heart J. 2015; 36(2):83–93b. https://doi.org/10.1093/eurheartj/ehu458 PMID: 25492627
11. Kunzli N. Reduce air pollution to reduce the burden of cardiovascular diseases! Eur Heart J. 2015; 36 (28):1779–81. PMID: 26413593
12. Pope CA, Bhatnagar A, McCracken J, Abplanalp WT, Conklin DJ, O'Toole TE. Exposure to Fine Particulate Air Pollution Is Associated with Endothelial Injury and Systemic Inflammation. Circ Res. 2016; 119: 1204–14. https://doi.org/10.1161/CIRCRESAHA.116.309279 PMID: 27780829
13. Pope CA, 3rd, Burnett RT, Thurston GD, Thun MJ, Calle EE, Krewski D, et al. Cardiovascular mortality and long-term exposure to particulate air pollution: epidemiological evidence of general pathophysiological pathways of disease. Circulation. 2004; 109(1):71–7. https://doi.org/10.1161/01.CIR.0000108927.80044.7F PMID: 14676145
14. DeJarnett N, Conklin DJ, Riggs DW, Myers JA, O'Toole TE, Hamzeh I, et al. Acrolein exposure is associated with increased cardiovascular disease risk. Journal of the American Heart Association. 2014; 3 (4).
15. O'Toole TE, Hellmann J, Wheat L, Haberzettl P, Lee J, Conklin DJ, et al. Episodic exposure to fine particulate air pollution decreases circulating levels of endothelial progenitor cells. Circulation research. 2010; 107(2):200–3. https://doi.org/10.1161/CIRCRESAHA.110.222679 PMID: 20595651
16. Werner N, Kosiol S, Schiegl T, Ahlers P, Walenta K, Link A, et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med. 2005; 353(10):999–1007. https://doi.org/10.1056/NEJMoa043814 PMID: 16148285
17. Wheat LA, Haberzettl P, Hellmann J, Baba SP, Bertke M, Lee J, et al. Acrolein inhalation prevents vascular endothelial growth factor-induced mobilization of flk-1+/sca-1+ cells in mice. Arterioscler Thromb Vasc Biol. 2011; 31(7):1598–606. https://doi.org/10.1161/ATVBAHA.111.227124 PMID: 21527748
18. Waidyanatha S, Rothman N, Li G, Smith MT, Yin S, Rappaport SM. Rapid determination of six urinary benzene metabolites in occupationally exposed and unexposed subjects. Anal Biochem. 2004; 327 (2):184–99. https://doi.org/10.1016/j.ab.2004.01.008 PMID: 15051535
19. Man CN, Gam LH, Ismail S, Lajis R, Awang R. Simple, rapid and sensitive assay method for simultaneous quantification of urinary nicotine and cotinine using gas chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2006; 844(2):322–7. https://doi.org/10.1016/j.jchromb.2006.07.029 PMID: 16908224
20. Charbotel B, Fervers B, Droz JP. Occupational exposures in rare cancers: A critical review of the literature. Crit Rev Oncol Hematol. 2014; 90(2):99–134. https://doi.org/10.1016/j.critrevonc.2013.12.004 PMID: 24387944
21. Snyder R. Leukemia and benzene. Int J Environ Res Public Health. 2012; 9(8):2875–93. https://doi.org/10.3390/ijerph9082875 PMID: 23066403
22. Chow PW, Abdul Hamid Z, Chan KM, Inayat-Hussain SH, Rajab NF. Lineage-related cytotoxicity and clonogenic profile of 1,4-benzoquinone-exposed hematopoietic stem and progenitor cells. Toxicology

and applied pharmacology. 2015; 284(1):8–15. https://doi.org/10.1016/j.taap.2015.01.016 PMID: 25645895

23. Lan Q, Zhang L, Li G, Vermeulen R, Weinberg RS, Dosemeci M, et al. Hematotoxicity in workers exposed to low levels of benzene. Science. 2004; 306(5702):1774–6. https://doi.org/10.1126/science.1102443 PMID: 15576619
24. Schnatter AR, Glass DC, Tang G, Irons RD, Rushton L. Myelodysplastic syndrome and benzene exposure among petroleum workers: an international pooled analysis. J Natl Cancer Inst. 2012; 104 (22):1724–37. https://doi.org/10.1093/jnci/djs411 PMID: 23111193
25. USC B. State & county quickfacts: Jefferson County, Kentucky. 2013 [Available from: http://quickfacts.census.gov/qfd/states/21/21111.html.
26. DeJarnett N, Yeager R, Conklin DJ, Lee J, O'Toole TE, McCracken J, et al. Residential Proximity to Major Roadways Is Associated With Increased Levels of AC133+ Circulating Angiogenic Cells. Arterioscler Thromb Vasc Biol. 2015; 35(11):2468–77. https://doi.org/10.1161/ATVBAHA.115.305724 PMID: 26293462
27. Mansi A, Bruni R, Capone P, Paci E, Pigini D, Simeoni C, et al. Low occupational exposure to benzene in a petrochemical plant: modulating effect of genetic polymorphisms and smoking habit on the urinary t,t-MA/SPMA ratio. Toxicol Lett. 2012; 213(1):57–62. https://doi.org/10.1016/j.toxlet.2011.02.001 PMID: 21300142
28. Ruppert T, Scherer G, Tricker AR, Adlkofer F. trans,trans-muconic acid as a biomarker of non-occupational environmental exposure to benzene. Int Arch Occup Environ Health. 1997; 69(4):247–51. PMID: 9137998
29. Stevens JF, Maier CS. Acrolein: sources, metabolism, and biomolecular interactions relevant to human health and disease. Mol Nutr Food Res. 2008; 52(1):7–25. https://doi.org/10.1002/mnfr.200700412 PMID: 18203133
30. Anderson MM, Hazen SL, Hsu FF, Heinecke JW. Human neutrophils employ the myeloperoxidase-hydrogen peroxide-chloride system to convert hydroxy-amino acids into glycolaldehyde, 2-hydroxypropanal, and acrolein. A mechanism for the generation of highly reactive alpha-hydroxy and alpha,beta-unsaturated aldehydes by phagocytes at sites of inflammation. J Clin Invest. 1997; 99(3):424–32. https://doi.org/10.1172/JCI119176 PMID: 9022075
31. Uchida K. Current status of acrolein as a lipid peroxidation product. Trends Cardiovasc Med. 1999; 9 (5):109–13. PMID: 10639724
32. Blank IH, McAuliffe DJ. Penetration of benzene through human skin. J Invest Dermatol. 1985; 85 (6):522–6. PMID: 4067326
33. Lindstrom AB, Highsmith VR, Buckley TJ, Pate WJ, Michael LC. Gasoline-contaminated ground water as a source of residential benzene exposure: a case study. J Expo Anal Environ Epidemiol. 1994; 4 (2):183–95. PMID: 7549473
34. Mohamed MF, Kang D, Aneja VP. Volatile organic compounds in some urban locations in United States. Chemosphere. 2002; 47(8):863–82. PMID: 12079081
35. Weisel CP. Benzene exposure: an overview of monitoring methods and their findings. Chem Biol Interact. 2010; 184(1–2):58–66. https://doi.org/10.1016/j.cbi.2009.12.030 PMID: 20056112
36. Kondo T, Hayashi M, Takeshita K, Numaguchi Y, Kobayashi K, Iino S, et al. Smoking cessation rapidly increases circulating progenitor cells in peripheral blood in chronic smokers. Arterioscler Thromb Vasc Biol. 2004; 24(8):1442–7. https://doi.org/10.1161/01.ATV.0000135655.52088.c5 PMID: 15191940
37. Friedrich EB, Walenta K, Scharlau J, Nickenig G, Werner N. CD34-/CD133+/VEGFR-2+ endothelial progenitor cell subpopulation with potent vasoregenerative capacities. Circ Res. 2006; 98(3):e20–5. https://doi.org/10.1161/01.RES.0000205765.28940.93 PMID: 16439688
38. Bard D, Kihal W, Schillinger C, Fermanian C, Segala C, Glorion S, et al. Traffic-related air pollution and the onset of myocardial infarction: disclosing benzene as a trigger? A small-area case-crossover study. PLoS One. 2014; 9(6):e100307. https://doi.org/10.1371/journal.pone.0100307 PMID: 24932584
39. Wu XR, Xue M, Li XF, Wang Y, Wang J, Han QL, et al. Phenolic metabolites of benzene inhibited the erythroid differentiation of K562 cells. Toxicology letters. 2011; 203(3):190–9. https://doi.org/10.1016/j.toxlet.2011.03.012 PMID: 21414390
40. Badham HJ, Winn LM. In utero and in vitro effects of benzene and its metabolites on erythroid differentiation and the role of reactive oxygen species. Toxicology and applied pharmacology. 2010; 244 (3):273–9. https://doi.org/10.1016/j.taap.2010.01.002 PMID: 20083130
41. Badham HJ, Winn LM. In utero exposure to benzene disrupts fetal hematopoietic progenitor cell growth via reactive oxygen species. Toxicol Sci. 2010; 113(1):207–15. https://doi.org/10.1093/toxsci/kfp242 PMID: 19812361

42. Sarkar M, Muhammad-Kah R, Liang Q, Kapur S, Feng S, Roethig H. Evaluation of spot urine as an alternative to 24h urine collection for determination of biomarkers of exposure to cigarette smoke in adult smokers. Environ Toxicol Pharmacol. 2013; 36(1):108–14. https://doi.org/10.1016/j.etap.2013.03.001 PMID: 23603463

43. Matsunaga N, Ikeda M, Takiguchi T, Koyanagi S, Ohdo S. The molecular mechanism regulating 24-hour rhythm of CYP2E1 expression in the mouse liver. Hepatology. 2008; 48(1):240–51. https://doi.org/10.1002/hep.22304 PMID: 18537186

44. Roberts BJ, Song BJ, Soh Y, Park SS, Shoaf SE. Ethanol induces CYP2E1 by protein stabilization. Role of ubiquitin conjugation in the rapid degradation of CYP2E1. J Biol Chem. 1995; 270(50):29632–5. PMID: 8530344

45. Choi YH, Kim JH, Lee BE, Hong YC. Urinary benzene metabolite and insulin resistance in elderly adults. Sci Total Environ. 2014; 482–483:260–8. https://doi.org/10.1016/j.scitotenv.2014.02.121 PMID: 24657371

46. Wiwanitkit V. Benzene exposure and hypertension: an observation. Cardiovasc J Afr. 2007; 18(4):264–5. PMID: 17940673